MIGENIX likes to pick up compounds after they've been discovered, and shepherd them through to late-stage clinical development. After that point, the company is happy to license them out and hopefully reap the benefits. MIGENIX has partnered with Cadence Pharmaceuticals to shoulder the cost of putting its omiganan gel through Phase III clinical trials for use in preventing catheter-related infections. Cutanea Life Sciences holds the rights to develop omiganan as an acne treatment. Other clinical and pre-clinical drug candidates in the company's pipeline include potential treatments for Hepatitis B and C, blood infections, and neuro-degenerative diseases.

Cyprotex PLC is a holding company, which is engaged in the provision of in vitro and in silico ADMET/PK (Absorption, Distribution, Metabolism, Excretion, Toxicity/Pharmacokinetic) information to the pharmaceutical industry. The Company developed a suite of services and technologies known as Cloe (Cyprotex Lead Optimisation Engine). It combines in vitro screening with pharmacokinetic prediction system to offer an integrated suite of ADME services to the pharmaceutical and biotechnology companies worldwide. During the year ended December 31, 2008, the Company introduced a new Cloe product line, Cloe Select, which focuses on studies performed of drug discovery or preclinical development stage. Its subsidiaries include Cyprotex Discovery Ltd, Cyprotex Research Ltd and Cyprotex North America, Inc.

Caraco Pharmaceutical Laboratories, Ltd. was founded in 1984 and is based in Detroit, Michigan. Caraco Pharmaceutical Laboratories, Ltd. is a subsidiary of Sun Pharmaceutical Industries Limited. Caraco Pharmaceutical Laboratories, Ltd. (Caraco) is engaged in the business of developing, manufacturing, marketing and distributing generic and private-label pharmaceuticals to wholesalers, distributors, warehousing and non-warehousing chain drugstores and managed care providers, throughout the United States and Puerto Rico. During the fiscal year ended March 31, 2009 (fiscal 2009), Caraco received United States Food and Drug Administration (FDA) approval for eight abbreviated new drug applications (ANDAs) relating to three products. It had filed 10 ANDAs relating to nine products with the FDA during fiscal 2009. This brings Caraco’s total number of ANDAs pending approval by the FDA to 29 (including four tentative approvals) relating to 25 products as of March 31, 2009.

Protide Pharmaceuticals is pro-cell. The firm focuses on developing new technologies for cellular and transfusion therapies, including gene therapies, to treat cancer and genetic disorders and to improve cell transplantation and engineering. To fund its work, Protide sells nearly 20 products under the Celox Laboratories brand to its academic, drug, and diagnostic research clients around the world. These products include serum-free growth mediums and supplements, as well as solutions used to cryopreserve cells and tissues. ICN Pharmaceuticals has a non-exclusive global marketing agreement for certain products. Protide also has a private-label manufacturing deal with a division of Sigma-Aldrich.

Hoffmann-La Roche, Inc., also known as Roche, is a research-oriented pharmaceutical company. It provides medications in the areas of infectious diseases, metabolic diseases, neurology, oncology, transplantation and virology, AIDS, cardiovascular diseases, central nervous system disorders, and dermatology. Hoffmann-La Roche, Inc. was formerly known as Roche Chemical Works and changed its name to Hoffmann-La Roche Inc. in January 1929. The company was founded in 1905 and is headquartered in Nutley, New Jersey. It has research centers in Basel, Switzerland; Nutley, New Jersey; Penzberg, Germany; Shanghai, China; and Palo Alto, California. Hoffmann-La Roche, Inc. operates as a subsidiary of Roche Holding AG.

Founded in 1929, the not-for-profit organization is a leading researcher of human diseases, their causes, and their potential cures. Much of its research into mammalian genetics is focused on mice, which share a similar genetic makeup to humans. In addition to its own research in areas such as cancer, immunology, and metabolic disease, the organization maintains colonies of mice and supplies them under the brand name JAX to other laboratories around the globe. Additionally, The Jackson Laboratory offers educational programs -- including internships, workshops, and predoctoral programs -- for both current and future scientists.

SurModics, Inc. Company was founded in 1979 and is headquartered in Eden Prairie, Minnesota. SurModics, Inc. engages in the development, manufacture, and sale of surface modification and drug delivery technologies to the healthcare industry. The company operates through four business units: Cardiovascular, Ophthalmology, SurModics Pharmaceuticals, and In Vitro Technologies. The Cardiovascular business unit supports the drug delivery and surface modification needs of cardiovascular customers by providing drug delivery polymers and coating technologies, including advanced lubricity (slippery) coatings that ease placement and maneuverability of medical devices in the body. The Ophthalmology business unit develops drug delivery systems for various drugs and other bioactive agents developed by pharmaceutical and ophthalmology companies for the treatment of serious eye diseases.The SurModics Pharmaceuticals business unit specializes in proprietary injectable microparticles and implants based on biodegradable polymers to provide sustained delivery of drugs, as well as supplies biodegradable polymers to corporate and academic customers. The In Vitro Technologies business unit specializes in in vitro diagnostic products and technologies for the biomedical research and medical diagnostic markets. Its products and technologies include protein stabilization reagents, substrates, recombinant autoimmune antigens, surface chemistry technologies for nucleic acid and protein immobilization, and diagnostic format intellectual property. The company markets its technologies and products through sales professionals, as well as sales and marketing relationships with third-parties worldwide. It has collaboration agreements with Genzyme Corporation to develop novel drug delivery solutions with an initial focus on peptide delivery.

MDS Pharma Services saves drugmakers time and energy when it comes to drug discovery. The company, a subsidiary of MDS, is a provider of contract research and development services for pharmaceutical and biotechnology companies. Through facilities in the Americas, Asia, and Europe, MDS Pharma Services provides its clients with early-stage clinical research and development services, such as consulting, target discovery, lead optimization, regulatory assistance, and Phase I-phase IIa testing. It employs an international network of scientists that serve as testing investigators. MDS Pharma has been put up for sale by parent company MDS.

Taisho Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company. Taisho Company, along with its subsidiaries and associated companies, operates in two business segment. The Self Medication segment is engaged in the research, development, manufacture and sale of self-medication pharmaceuticals, quasi drugs and food products. This segment is also involved in the provision of insurance services, logistics services, printing services, as well as real estate leasing, management and operation services. The Prescribed Medication segment is engaged in the development, manufacture and sale of prescribed pharmaceuticals. Taisho Company has 23 subsidiaries and three associated companies. The Company acquired 97.97% stake in PT Bristol-Myers Squibb Indonesia Tbk. on October 31, 2009.

Diagnostic HYBRIDS was founded in 1983 by Ohio University professors and private investor and entrepreneur Dr. Wilfred Konneker. It has agreed to be acquired by Quidel for $130 million. Diagnostic HYBRIDS will tell you which kind you have. The company develops and markets cell culture kits to help identify various viruses and endocrine diseases. Its product line include kits to detect a wide range of influenza viruses, herpes simplex viruses 1 and 2, Chlamydia and Cytomegalovirus, which includes the viruses that cause chicken pox and mononucleosis. Other kits demonstrate thyroid functioning. The biotech firm also develops and sells cell-based detection products.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.